Captopril 是一种含巯基的，具有口服活性的血管紧张素转换酶(ACE)抑制剂 ，IC50=0.025 μM，广泛应用于高血压和充血性心力衰竭的研究。Captopril 也是NDM-1抑制剂，IC50=7.9 μM。

Captopril is a potent and specific inhibitor of peptidyl-dipeptidase A. It blocks the conversion of angiotensin I to angiotensin II, a vasoconstrictor and important regulator of arterial blood pressure.

Binding assay: Cells are plated in 24-well plates and cultured until confluence. Before the experiment, the cells are washed three times with 0.5 mL per well of DMEM at room temperature. After removal of the medium, 400 μL binding DMEM is added and the plate is then left for 15 min at 37 ℃. For saturation binding assays cells are incubated with increasing concentrations [3H]Candesartan (final concentrations between 0.15 nM and 15 nM) in a final volume of 0.5 mL at 37 ℃ for 5 min to 180 min. For competition binding assays 50 μL of buffer or 50 μL of buffer containing increasing concentrations of unlabelled Candesartan is added. After 30 min, 50 μL of buffer containing [3H]Candesartan (final concentration 1.1 nM) or [3H]Candesartan (final concentration 1.0 nM) is added, and the cells are further incubated for 30 min at 37 ℃.

62571-86-2

C9H15NO3S

217.29

SQ 14225;SQ-14534;卡托普利;SA333;甲巯丙脯酸

H2O:21.7 mg/mL (100 mM)
DMSO:21.7 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years